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Background: The significance of left atrial volume index (LAVI) for predicting outcomes
in patients with mitral stenosis (MS) has been unclear, even though rheumatic MS is
known to be associated with left atrium enlargement and functional deterioration.
Hypothesis: The current study aimed to investigate the prognostic value of LAVI,
based on the severity in patients with rheumatic MS.
Methods: We retrospectively reviewed 611 patients with pure rheumatic MS. The
prognostic value of LAVI and the effect of MS severity on the prognostic value of
LAVI for events were evaluated. The events were defined as a composite end-point
that included all-cause death, heart failure admission, mitral valve replacement, per-
cutaneous mitral valvuloplasty, and stroke.
Results: There were 236 (38.6%) overall events during a median follow-up of
8 months. The optimal LAVI cutoff for the prognostic threshold was 57 ml/m2. The
MS severity had a significant effect on the prognostic value of LAVI. A LAVI >57 ml/
m2 was a prognostic value for events in progressive MS (hazard ratio [HR]: 2.40, 95%
confidence interval [CI]: 1.41–5.40, p = .004) and in patients with severe MS (HR:
1.70, 95% CI: 1.06–2.74, p = .029), but it was not prognostic in patients with very
severe MS (HR: 1.02, 95% CI: 0.56–1.84, p = .955).
Conclusions: The prognostic value of LAVI varies and is dependent on the MS severity.
A LAVI >57 mL/m2 was independently associated with poor outcomes in patients with
progressive MS, while this association was minimized in patients with severe MS.
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1 | INTRODUCTION
The left atrial volume index (LAVI) is a known prognostic marker for car-
diovascular outcomes in various cardiovascular diseases, including heart
failure, hypertrophic cardiomyopathy, and ischemic heart disease, as
well as in the general population.1-4 The prognostic role of LAVI in val-
vular heart disease has also been applied in patients with mitral regurgi-
tation (MR),5,6 aortic stenosis,7-9 and aortic regurgitation.10 However,
the value of LAVI for predicting outcomes in patients with mitral steno-
sis (MS) has been unclear, even though rheumatic MS is known to be
closely associated with left atrium enlargement, stiffening, and func-
tional deterioration.11 One report has indicated that LAVI did not pre-
dict clinical outcomes in patients with MS.12
We recently found that LAVI can act as a prognostic marker for
outcomes in patients with progressive MS, which is defined as MS
patients with the mitral valve area (MVA) larger than 1.5 cm2.13
Received: 22 October 2020 Revised: 29 December 2020 Accepted: 30 December 2020
DOI: 10.1002/clc.23544
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
364 Clin Cardiol. 2021;44:364–370.wileyonlinelibrary.com/journal/clc
Progressive MS is a less severe stage during disease progression in
MS. Therefore, we hypothesized that the prognostic value of LAVI for
MS would differ according to the severity of the disease, and this
might cause discordant results for the prognostic value of LAVI in
patients with MS. We aimed to investigate the effect of MS severity
on the prognostic value of LAVI in a large cohort of patients with MS,
categorized as progressive MS, severe MS, and very severe MS. We
additionally sought to assess associated factors for an enlarged left
atrium other than the severity of MS in those patients.
2 | METHODS
2.1 | Study population
We analyzed patients with rheumatic MS who underwent echocardi-
ography between 2006 and 2015 at a tertiary referral center for val-
vular heart disease in Korea. Exclusion criteria were as follows:
patients with >1+ MR, >1+ aortic regurgitation and/or more than mild
aortic stenosis, patients with congenital or myopathic lesions that
could affect pulmonary artery pressure, patients with a history of prior
percutaneous mitral valvuloplasty (PMV), those who had undergone
planned mitral valve replacement (MVR) or PMV before the echocar-
diographic examination, and those who received MVR or PMV within
30 days after the index echocardiography examination. Demographic
characteristics including age, sex, anticoagulation, history of prior
stroke, and body surface area were confirmed by chart review. Sys-
tolic and diastolic blood pressure were measured before the echocar-
diography. Therefore, in total, 611 patients with pure rheumatic MS
were included. This study was approved by the ethical committee of
Yonsei University, Severance Hospital, Seoul, Korea. The need to
obtain informed consent was waived for the retrospectively obtained
data for this non-interventional study.
2.2 | Echocardiography
Two-dimensional and Doppler echocardiography were performed
according to the American Society of Echocardiography (ASE) guide-
lines.14 Left ventricular (LV) end-diastolic dimension (EDD), LV end-
systolic dimension (ESD), septal wall thickness, and posterior wall
thickness were measured from the M-mode. LV ejection fraction
(EF) was calculated using LV EDD and ESD. LV mass was calculated
using the formula, according to the ASE guidelines. The LV mass index
was defined as an LV mass indexed for body surface area. LV
hypertrophy was defined as LV mass index ≥115 g/m2 for men and
≥95 g/m2 for women.14 The left atrial volume was calculated using
the biplane area-length method according to ASE guidelines.14 Two-
dimensional volumetric measurements were based on left atrial areas
measures by tracings of the blood-tissue interface and left atrial
lengths on apical four- and two-chamber views (Figure S1). LAVI was
defined as left atrial volume indexed for body surface area. The MVA
was assessed by two-dimensional planimetry. MS was categorized
according to the MVA; progressive MS (1.5 cm2 < MVA ≤2.0 cm2),
severe MS (1.0 cm2 < MVA ≤1.5 cm2), and very severe MS (MVA
≤1.0 cm2).15
The mean diastolic transmitral pressure gradient was measured
from a continuous wave Doppler signal across the mitral valve by trac-
ing its envelope. The calculated systolic pulmonary artery pressure
was defined as 4 × (maximum velocity of the tricuspid regurgitant
jet)2 + right atrial pressure. Right atrial pressure was estimated by
measuring the inferior vena cava diameter.16 Stroke volume was cal-
culated using the LV outflow tract diameter and the LV outflow tract
flow pulsed-wave Doppler signal. The stroke volume index was
defined as stroke volume indexed for body surface area.
2.3 | Study endpoint
Patients were followed across a median of 41 months (Interquartile
range: 8–84 months) for a composite end-point that included all-
cause death, inpatient admissions for heart failure, MVR, PMV, and
incidence of stroke. The occurrence of any of the clinical events was
ascertained by a review of hospital records and by telephone inter-
views, as necessary.
2.4 | Statistics
Demographic characteristics are reported as percentages or as the
mean ± SD. The patient groups were compared using chi-square sta-
tistics for categorical variables and the Student's t-test for continuous
variables. Receiver operating characteristic (ROC) curves were used to
determine the sensitivity and specificity of LAVI in predicting the pri-
mary outcomes and to determine the optimal cut-off value for contin-
uous variables. Univariable and multivariable Cox proportional-
hazards regression models reporting the hazard ratio (HR) and 95%
confidence interval (CI) was employed to determine potential useful
variables for predicting event-free survival following echocardiogra-
phy. Variables with statistical significance in univariable analysis were
entered into the multivariable Cox proportional hazard model, as well
as age and sex. Kaplan–Meier survival curves were employed to plot
all events according to the time-to-first event. To determine potential
independent associations between variables and LAVI, binary logistic
regression was applied. Variables displaying statistical significance in
univariable analysis were entered into a multivariable binary logistic
regression model, reporting the odds ratio (OR) and 95% CI. A p value
<.05 was considered statistically significant.
3 | RESULTS
Table 1 demonstrates the baseline characteristics of the study popula-
tion. There were 207 patients with progressive MS, 281 patients with
severe MS, and 123 patients with very severe MS from the overall
611 patients with MS. The mean age was 60 ± 12, and 76.4% of the
CHO ET AL. 365
patients were women. Patients with very severe MS were younger
than those with progressive and severe MS (56 ± 12 years vs. 62
± 12 years vs. 60 ± 12 years). There were no significant differences in
the sex between the groups. LV hypertrophy was more common in
patients with progressive and severe MS compared to those with very
severe MS (37.7% vs. 32.7% vs. 16.2%). The outcomes of the popula-
tion are shown in Table S1. There were 236 (38.6%) overall events,
including 3 cardiac deaths (0.5%), 24 heart failure admissions (3.9%),
129 MVRs (21.1%), 51 PMVs (8.3%), and 29 strokes (4.7%). There
were 33 (15.9%) events in patients with progressive MS, 118 (42.0%)
events in patients with severe MS, and 85 (69.1%) events in patients
with very severe MS.
The optimal cut-off value for predicting overall events according
to the ROC curves for the LAVI was 57 ml/m2, in which the area
under curve (AUC) was 0.657, the sensitivity was 76.2% and specific-
ity was 50.2%. We categorized patients into two LAVI groups as fol-
lows: LAVI >57 ml/m2 and LAVI ≤57 ml/m2 for a comparison. To
confirm optimal LAVI cut-offs at each MS severity grade, there was
additional investigation of the optimal cut-off value for predicting
overall events according to the ROC curves for LAVI in each of the
progressive, severe, and very severe MS groups. The optimal cut-off
for LAVI was 51 ml/m2 for progressive MS (AUC: 0.693, sensitiv-
ity = 77.1%, specificity = 57.9%), 52 ml/m2 for severe MS (AUC:
0.531, sensitivity = 81.2%, specificity = 29.6%), and 58 ml/m2 for very
severe MS (AUC: 0.529; sensitivity = 73.6%, specificity = 26.4%).
Table 2 demonstrates determinants of clinical outcomes. In
univariable analysis, atrial fibrillation (HR: 1.46, 95% CI: 1.12–1.90,
p = .005), presence of symptom (HR: 1.41, 95% CI: 1.09–1.83,
p = .009), LAVI >57 ml/m2 (HR: 2.01, 95% CI: 1.51–2.70, p < .001),
and MS grade (HR: 2.63, 95% CI: 1.79–3.88, p < .001 for severe MS;
HR: 4.34, 95% CI: 2.90–6.48, p < .001 for very severe MS) were asso-
ciated with the incident of events. However, a LAVI >57 ml/m2 (HR:
1.41, 95% CI: 1.01–1.98, p = .048) and MS grade (HR: 2.29, 95% CI:
1.54–3.41, p < .001 for severe MS; HR: 3.44, 95% CI:2.23–5.32,
p < .001 for very severe MS) were independently associated with
events, after adjusting for other confounding factors, suggesting that
LAVI was the only predictor for events, excluding MS severity.
Figure 1 demonstrates the Kaplan–Meier curve for outcomes,
according to LAVI, in overall and asymptomatic patients. A LAVI
>57 ml/m2 was associated with poor outcomes in the overall
TABLE 1 Baseline characteristics
Variable Overall (n = 611)
MS grade
Progressive (n = 207) Severe (n = 281) Very severe (n = 123)
Demographics
Age, years 60 ± 12 62 ± 12 60 ± 12 56 ± 12a,b
Female sex, n (%) 467 (76.4) 156 (75.4) 217 (77.2) 94 (76.4)
AF, n (%) 327 (53.5) 86 (41.5) 160 (56.9)a 81 (65.8)a
Anticoagulation, n (%) 339 (55.5) 75 (36.2) 174 (61.9) 90 (73.1)a,b
Prior stroke, n (%) 88 (14.4) 21 (10.1) 43 (15.3) 24 (19.5)
Symptomatic, n (%) 209 (34.2) 55 (26.6) 100 (35.6)a 54 (43.9)a
Body surface area, m2 1.60 ± 0.16 1.63 ± 0.17 1.60 ± 0.16a 1.56 ± 0.14a,b
Systolic BP, mm Hg 119.5 ± 19.1 122.3 ± 22.1 118.0 ± 16.4 116.5 ± 16.7
Diastolic BP, mm Hg 74.7 ± 13.1 77.6 ± 15.0 72.6 ± 11.1a 72.8 ± 11.6a
Echocardiography
LV EDD, mm 48.1 ± 4.5 48.6 ± 4.7 48.2 ± 4.4 46.9 ± 4.3a,b
LV ESD, mm 32.3 ± 4.2 32.5 ± 4.5 32.4 ± 4.1 31.9 ± 3.8
LV EF, % 64.0 ± 7.2 64.8 ± 7.6 63.8 ± 7.3 63.3 ± 6.2
LV mass index, g/m2 91.1 ± 23.0 95.8 ± 22.3 91.3 ± 21.7a 82.8 ± 24.8a,b
LAVI, ml/m2 68.0 ± 32.6 54.8 ± 24.4 72.5 ± 30.8a 83.7 ± 39.3a,b
MVA, cm2 1.33 ± 0.36 1.74 ± 0.14 1.24 ± 0.14a 0.82 ± 0.14a,b
MDPG, mm Hg 6.0 ± 3.2 3.6 ± 1.1 5.9 ± 2.2a 10.1 ± 3.4a,b
SPAP, mm Hg 34.5 ± 11.3 30.3 ± 8.6 33.8 ± 9.3a 43.6 ± 13.9a,b
Stroke volume index, ml/m2 39.0 ± 8.7 39.9 ± 9.1 38.8 ± 8.7 37.9 ± 8.0
LV hypertrophy, n (%) 190 (31.1) 78 (37.7) 92 (32.7) 20 (16.2)a,b
ap value <.05 compared to progressive MS.
bp value <.05 compared to severe MS.
Abbreviations: AF, atrial fibrillation; BP, blood pressure; EDD, end-diastolic dimension; EF, ejection fraction; ESD, end-systolic dimension; LAVI, left atrial
volume index; LV, left ventricular; MDPG, mean diastolic pressure gradient; MS, mitral stenosis; MVA, mitral valve area; SPAP, systolic pulmonary artery
pressure.
366 CHO ET AL.
population and in a subgroup of asymptomatic patients (all log-rank
p < .001).
Because interaction testing confirmed the effect of MS severity
on the LAVI prognostic value (interaction p < .001), we evaluated the
LAVI prognostic value according to the MS severity (Table 3). In
patients with progressive MS, a LAVI >57 ml/m2 was a prognostic
value for events (HR: 2.40, 95% CI: 1.41–5.40, p = .004), even after
adjusting for age, sex, atrial fibrillation, symptom, and MVA. In
patients with severe MS, this association was reduced but still existed
(HR: 1.70, 95% CI: 1.06–2.74, p = .029), while a LAVI >57 ml/m2 was
not prognostic for events in patients with very severe MS (HR: 1.02,
95% CI: 0.56–1.84, p = .955). Figure 2 demonstrates the Kaplan–
Meier curve for outcomes according to LAVI in each group: progres-
sive MS, severe MS, and very severe MS, respectively. A LAVI
>57 ml/m2 was associated with poor outcomes in patients with pro-
gressive MS (log-rank p = .002) and in patients with severe MS (log-
rank p = .004), whereas this association was not found in patients with
very severe MS (log-rank p = .814).




HR 95% CI p value HR 95% CI p value
Age 1.00 0.99–1.01 .387 1.00 0.99–1.01 .780
Sex 0.99 0.73–1.34 .954 0.98 0.72–1.32 .882
AF 1.46 1.12–1.90 .005 1.12 0.82–1.52 .483
Symptomatic 1.41 1.09–1.83 .009 1.26 0.97–1.63 .088
LAVI >57 ml/m2 2.01 1.51–2.70 <.001 1.41 1.01–1.976 .048
LVEF >50% 0.65 0.36–1.20 .169 -
MS grade
Progressive 1.00 - - 1.00 - -
Severe 2.63 1.79–3.88 <.001 2.29 1.54–3.41 <.001
Very severe 4.34 2.90–6.48 <.001 3.44 2.23–5.32 <.001
Abbreviations: AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio; LAVI, left atrial volume
index; LVEF, left ventricular ejection fraction; MS, mitral stenosis.
F IGURE 1 Kaplan–Meier curve
to demonstrate the outcomes
according to the left atrial volume
index. (A) overall population and
(B) asymptomatic patients
TABLE 3 Prognostic valuea of left
atrial volume index by mitral stenosis
severity
HR for events with
LAVI >57 ml/m2 95% CI p value
Progressive 2.40 1.41–5.40 .004
Severe 1.70 1.06–2.74 .029
Very severe 1.02 0.56–1.84 .955
aCox proportional hazards model for time to the event, adjusted for age, sex, atrial fibrillation, symptom,
and mitral valve area.
Abbreviations: CI, confidence interval; HR, hazard ratio; LAVI, left atrial volume index.
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Echocardiographic factors that correlated with an LAVI
>57. ml/m2 in patients with MS are shown in Table S2. In univariable
analysis, LV EDD and ESD, LV EF, LV hypertrophy, and MS grade
were all associated with a LAVI >57 ml/m2. However, LV hypertrophy
(OR: 2.09, 95% CI: 1.35–3.22, p = .001) and MS grade (OR: 4.12, 95%
CI: 2.75–6.18, p < .001 for severe MS; OR: 8.93, 95% CI: 5.11–15.62,
p < .001 for very severe MS) were independently associated factors
for LAVI >57 ml/m2, even after adjusting for various echocardio-
graphic variables. To assess association of LAVI and LV hypertrophy
at each MS severity category, the echocardiographic factors that cor-
related with a LAVI >57 ml/m2 were assessed in each MS severity cat-
egory, respectively. LV hypertrophy was independently associated
with LAVI >57 ml/m2 in progressive MS (OR: 2.22, 95% CI:
1.26–3.90, p = .006) and severe MS (OR: 1.43, 95% CI: 1.00–2.06,
p = .048), even with adjustments for LV EDD, LV ESD, and LV EF;
however, it did not show statistically significant association in very
severe MS (OR: 2.78, 95% CI: 0.60–12.91, p = .189).
4 | DISCUSSION
The main findings of this study are that (1) the prognostic value of
LAVI varies and is dependent upon the MS severity and (2) a large
LAVI was independently associated with poor outcomes in patients
with progressive MS, while this association weakens in patients with
severe MS and the prognostic value of LAVI was not seen in patients
with very severe MS.
4.1 | Left atrium in mitral valve disease
LAVI is a known prognostic marker for cardiovascular outcomes in vari-
ous cardiovascular diseases that involve the left ventricle, as well as in
the general population.1-4 This is primarily because left atrial enlarge-
ment is a marker for LV diastolic dysfunction and elevated filling
pressure. An increase in LV filling pressure and left atrial pressure
results in enlargement of left atrial size and functional deterioration.
Mitral valve disease, either stenosis or regurgitation, is the main
cause for left atrial enlargement through elevation of left atrial pres-
sure. Therefore, left atrial enlargement usually reflects the severity
and duration of mitral valve disease. However, the predictive role of
LAVI in MS patients has been less clear,11 because it differs from the
well-known prognostic value of LAVI in patients with MR,5,6 although
a giant left atrium has been frequently noted in patients with long-
standing rheumatic MS.17
Some reports have indicated that MR rather than MS was an
important predictor of left atrial reverse remodeling after mitral valve
surgery,18 suggesting differences in left atrial remodeling and the
mechanics of MS compared to MR. The plausible explanation for the
difference in left atrial remodeling between MS and MR is that
increased left atrial work caused by pressure overload in MS results in
severe left atrial fatigue and failure over time.19 Electron microscopy
study has also reported that endothelial cell surface changes are more
severe in patients with MS than in those with MR, which suggests
severe endothelial damage of the left atrial wall resulting from heavy
pressure overload in patients with MS.20
Our results indicated that the prognostic role of LAVI was not
found in patients with very severe MS of MVA ≤1.0 cm2, which is
consistent with the study that showed a lack of prognostic value for
LAVI in MS.12 However, our data also suggest that there is an interac-
tion of MS severity in the prognostic role of LAVI. That is, as the MVA
becomes smaller, the LAVI prognostic value becomes weaker. Inter-
estingly, patients with progressive MS and severe MS, who had prog-
nostic values for LAVI, were older than those with very severe
MS. This fact suggests that those patients might be a subgroup of the
population that have experienced less severe pressure overload in the
left atrium over longer duration. Moreover, aging is a well-known risk
factor for LV diastolic dysfunction, and therefore, we can hypothesize
that LV diastolic dysfunction might be a cause for left atrial enlarge-
ment in those subgroups of the population.
F IGURE 2 Kaplan–Meier curve to demonstrate the outcomes according to the left atrial volume index. (A) progressive MS, (B) severe MS,
and (C) very severe MS. MS, mitral stenosis
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4.2 | Left ventricle influence on the left atrium
in MS
Despite the long-held belief that rheumatic MS is an isolated disease of
the stenotic mitral valve, several studies have suggested LV myocardial
abnormalities in a subset of patients with rheumatic MS.21-23 We previ-
ously reported that LV diastolic dysfunction and increased LV diastolic
pressure is a mechanism for the low-gradient phenomenon in subsets
of MS, which is commonly found in elderly patients with atrial fibrilla-
tion.22 From the current study, we also found that LV hypertrophy was
independently associated with a large LAVI. Because LV hypertrophy is
a well-known cause of LV diastolic dysfunction and an increase in LV
stiffness, we can speculate that LV diastolic dysfunction in elderly
patients affects the left atrial pressure and volume even in MS patients,
similar to other cardiovascular diseases involving the left ventricle.
Interestingly, the presence of LV hypertrophy was more prevalent
in the order of progressive MS, severe MS, and very severe
MS. Therefore, the influence of LV properties might be more promi-
nent in progressive MS, which showed the most powerful prognostic
value of the LAVI on outcomes in the MS subgroups. LV hypertrophy
and associated LV diastolic dysfunction might aggravate left atrial
enlargement, and accelerate poor clinical outcomes in MS patients
with relatively larger MVAs. Therefore, LV hypertrophy and diastolic
dysfunction can be a treatment target for patients with MS with MVA
>1.0 cm2, especially in the elderly population with LV hypertrophy.24
Figure S2 demonstrates our hypothesis and a summary of determi-
nants for LAVI and the prognostic value in patients with MS, according
to the disease severity. To summarize, LAVI is determined by LV myo-
cardial properties and MS severity, and the prognostic value decreases
as the MVA decreases. For left atrial enlargement, LV myocardial prop-
erty is important in progressive MS, whereas its importance weakens
and MVA becomes more important in very severe MS.
4.3 | Limitations
The main limitation of the current study is that the results of this
study were based on retrospective analysis. However, patient medical
records and echocardiography were carefully reviewed. We defined
the presence of symptoms from clinical records, even though all medi-
cal records and echocardiography were reviewed carefully to minimize
any bias. The choice to perform surgery or another intervention was
made by each attending physician; therefore, it was not standardized
and may have been influenced by the patient's LAVI. However, since
LAVI is not included in the echocardiographic parameters for deter-
mining MS intervention in the current guideline,15,25 the LAVI would
not have had a significant effect on each physician's decision.
5 | CONCLUSION
The prognostic value of LAVI varies and is dependent upon the MS
severity. A LAVI >57 ml/m2 was independently associated with poor
outcomes in patients with progressive MS, while this association
weakened in patients with severe MS. The prognostic value of LAVI
was not identified in patients with very severe MS. LAVI was indepen-
dently associated with the presence of LV hypertrophy, suggesting
the influence of LV myocardial properties on LAVI in patients
with MS.
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